Instituto RosenbuschBUE:ROSE -3.07%37 Days Payable is 39.43 as of Dec. 2025, which is 50% below its 10-year median of 79.24. GuruFocus rates BUE:ROSE with a GF Score™ of 37/100 and a GF Value™ of ARS61.89 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 919 Drug Manufacturers companies, Instituto Rosenbusch ranks worse than 88.79% on this metric.
The historical rank and industry rank for Instituto Rosenbusch's Days Payable or its related term are showing as below:
BUE:ROSE'
s Days Payable Range Over the Past 10 Years
Min: 31.32 Med: 79.24 Max: 159.02
Current: 31.32
During the past 13 years, Instituto Rosenbusch's highest Days Payable was 159.02. The lowest was 31.32. And the median was 79.24.
BUE:ROSE's Days Payable is ranked worse than 88.79% of 919
companies
in the Drug Manufacturers industry
Industry Median: 90.69
vs BUE:ROSE: 31.32
Instituto Rosenbusch's Days Payable
declined
from Dec. 2024 (48.19) to Dec. 2025 (39.43).
It may suggest that Instituto Rosenbuschaccelerated paying its suppliers.
Instituto Rosenbusch Days Payable Related Terms
Instituto Rosenbusch Days Payable Historical Data
* Premium members only.
The historical data trend for Instituto Rosenbusch's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUE:ROSE vs ZTS, UTHR, VTRS: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Instituto Rosenbusch Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's Days Payable distribution charts can be found below:
* The bar in red indicates where Instituto Rosenbusch's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Instituto Rosenbusch's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Instituto Rosenbusch (BUE:ROSE) has a Days Payable of 39.43 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Instituto Rosenbusch and its competitors. This is 50% below median its historical median of 79.24. Over the past decade, Instituto Rosenbusch's Days Payable has ranged from 31.32 to 159.02. According to the industry distribution chart, Instituto Rosenbusch ranks #816 out of 919 companies in the Drug Manufacturers industry, placing it in the top 88.8%.
Is Instituto Rosenbusch's Days Payable too high?
Instituto Rosenbusch's current Days Payable of 39.43 is 50% below median its 10-year median of 79.24. Over the past 10 years, this metric has ranged from a low of 31.32 to a high of 159.02. The Drug Manufacturers industry median Days Payable is 90.69. Instituto Rosenbusch's value of 39.43 is 56.5% below this industry median. Based on the distribution chart, Instituto Rosenbusch ranks #816 out of 919 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Instituto Rosenbusch has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Instituto Rosenbusch ranks #816 out of 919 companies for Days Payable. This places Instituto Rosenbusch in the lower half of its industry. The industry median Days Payable is 90.69. Instituto Rosenbusch's value of 39.43 is 56.5% below this benchmark. Historically, Instituto Rosenbusch's own Days Payable has ranged from 31.32 to 159.02 over the past decade. While the company's 10-year median is 79.24 vs. the industry median of 90.69, Instituto Rosenbusch has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.69, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Instituto Rosenbusch's current Days Payable of 39.43 is 56.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Instituto Rosenbusch and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Instituto Rosenbusch's current Days Payable is 39.43, which is 50% below median its own 10-year median of 79.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS61.89, compared to a current price of ARS158.00 — trading 155.3% above its estimated fair value. The current Days Payable is 39.43, which is 50% below median its 10-year median of 79.24 and 56.5% below the Drug Manufacturers industry median of 90.69. Instituto Rosenbusch's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current Days Payable is 39.43 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?
Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued.
The current stock price of ARS158.00 is trading 155.3% above its estimated GF Value™ of ARS61.89.
GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.
Key valuation signals for BUE:ROSE:
Days Payable: 39.43 (50% below median its 10-year median of 79.24)
GF Value™: ARS61.89 vs. price of ARS158.00 (155.3% above fair value)
Industry Position: 56.5% below the Drug Manufacturers median (#816 of 919)
No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
37GF Score
Get the complete analysis for BUE:ROSE
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:ROSE has been successfully added to your 
